The Babak Lab shared a post on LinkedIn:
“Clinical Mondays: Lifyorli in platinum-resistant ovarian cancer.
The FDA has approved Lifyorli (relacorilant) in combination with chemotherapy for platinum-resistant ovarian cancer, a setting with limited treatment options.
Key Focus
The approval introduces a glucocorticoid receptor modulator as a strategy to overcome resistance to chemotherapy.
Key Insights
- Lifyorli works by inhibiting cortisol’s suppression of apoptosis, enhancing tumor sensitivity to chemotherapy.
- Approved in combination with nab-paclitaxel.
- Data from the pivotal ROSELLA trial showed a 35% reduction in the risk of death and a 4.1-month improvement in median OS.
- Represents a shift toward sensitizing tumors rather than directly targeting them.
Conclusion
This approval marks a significant shift toward modulating tumor biology to overcome resistance. By unlocking the apoptotic pathway, Lifyorli offers a potent new strategy for managing platinum-resistant disease.
- Image generated using Sora by OpenAI.
- A link to the full article can be found in the comments section.”
Other articles about FDA on OncoDaily.